CDC MMWR News Synopsis for June 11, 2015

MMWR- Morbidity and Mortality Weekly Report                          

MMWR News Synopsis for June 11, 2015

Health Effects of Gas Explosions and Other Petroleum Product Release Incidents — Seven States, 2010–2012

Understanding the characteristics of acute petroleum product releases can aid the public and utility workers in the development of preventive strategies and reduce the morbidity and mortality associated with such releases. Large mass-casualty gas explosions and catastrophic oil spills are widely reported and receive considerable regulatory attention. Smaller, less catastrophic releases are less likely to receive publicity, although study of these incidents might help focus and prioritize prevention efforts.  

Serogroup B Meningococcal Disease Outbreak and Carriage Evaluation at a College — Rhode Island, 2015

During a serogroup B meningococcal disease outbreak at a college in Rhode Island, 25 percent of students were found to have asymptomatic nasopharyngeal carriage of Neisseria meningitidis, though none were carrying the outbreak strain. In response to a serogroup B meningococcal disease outbreak at a college in Rhode Island, targeted antibiotic chemoprophylaxis of close contacts and a mass vaccination campaign with a recently-licensed serogroup B meningococcal (MenB) vaccine were implemented.

Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015

Certain persons aged ≥10 years at increased risk for meningococcal disease should receive serogroup B meningococcal vaccine. There are two serogroup B meningococcal (MenB) vaccines licensed in the United States, and approved for use in persons aged 10–25 years. The Advisory Committee on Immunization Practices (ACIP) recommends use of MenB vaccines among certain groups of people aged ≥10 years at increased risk for meningococcal disease.

Progress Toward Measles Elimination — South-East Asia Region, 2003–2013

To achieve measles elimination in the South-East Asia Region, additional efforts are needed in countries with < 95 percent 2-dose routine measles-containing vaccine (MCV) coverage, particularly in India and Indonesia. Such efforts should include strengthening routine immunization services, conducting periodic high-quality supplementary immunization activities (SIAs), strengthening measles case-based surveillance and laboratory diagnosis for measles, and using the measles elimination platform to integrate rubella and congenital rubella syndrome (CRS) control efforts.

Notes from the Field

•  Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoids — United States, January–May 2015

Read More>>